Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry (RegCOVID19)

Instituto de Investigación Marqués de Valdecilla

Status: Unknown

Conditions: SARS-CoV-2

Treatments: Drug: Patients with the treatment agains COVID19

Study type: Observational

Funder types: Other

Identifiers

NCT04347278

IDI-REM-2020-1

Details and patient eligibility

About

The infection caused by COVID19 worldwide makes it necessary to monitor drugs administered for the treatment of patients hospitalized with SARS-CoV-2. In order to know more about the efficacy and safety of the treatments used, researchers from the Cantabrian health service have developed an observational study, in the form of an ambispective registry, in which clinical data from patients treated with the different drugs currently recommended by the Spanish Agency of Medicines and Health Products (SAMHP) and the Ministry of Health, or others that may arise, are collected and analyzed.

Although the conduct of clinical trials is a priority at this time, we cannot lose the clinical experience that is currently being generated, which may allow us to improve the therapeutic strategies for future patients.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 1 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients of any age and gender, including minors and pregnant women.
• Hospital admission with diagnosis of COVID-19 according to clinical and microbiological criteria established by the Health Authorities and clinical practice (these may be modified based on the "Technical Document. Clinical management of COVID-19: hospital care" of the Ministry of Health).
• Patients receiving any specific treatment for COVID-19 disease (according to the "Technical Document. Clinical management of COVID-19: medical treatment" of the Ministry of Health, and "Available treatments for the management of respiratory infection by SARS-CoV-2" of the AEMPS).
• Patients admitted but not receiving specific treatment for COVID-19 disease

Exclusion criteria

• Patients who do not wish to give informed consent once requested.

Trial design

1,000 participants in 1 patient group

Patients receiving treatment for COVID19

Treatment:

Drug: Patients with the treatment agains COVID19